Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.70 |
| ▸ | MITF | O75030 | 1/20 | 0.70 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | XBP1 | P17861 | 1/20 | 0.70 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9664481 | 0.86 | RAB9A (0.54) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL1461789 | 0.82 | RAB9A (1.00) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL10813548 | 0.79 | RAB9A (0.70) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| Pyrazon SCHEMBL1858918 | 0.79 | RAB9A (0.70) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL9918817 | 0.79 | ALDH1A1 (0.51) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| Pyrazon SCHEMBL53824 | 0.79 | RAB9A (0.70) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL9240283 | 0.79 | RAB9A (0.70) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL13219321 | 0.76 | ALDH1A1 (0.70) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL4191657 | 0.76 | RAB9A (0.76) | RAB9AALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL9397355 | 0.76 | RAB9A (0.76) | RAB9AALDH1A1SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| US-7968711-B2 | Isoprenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol, 2-(3,5-Difluorophenyl)-5-hydroxypyridazin-3-one, 4-Bromo-2-(2,5-dichlorophenyl)-5-hydroxypyridazin-3-one; glaucoma or ocular hypertension | ALLERGAN, INC. (US) | 2011-06-28 | — | — | US | claimed |
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| EP-0413244-A2 | Process for separation and recycling of by-products from the wastewater of the synthesis of 5-amino-4-chloro-2-phenyl-3(2H)-pyridazinone | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | disclosed |
| US-7968711-B2 | Isoprenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol, 2-(3,5-Difluorophenyl)-5-hydroxypyridazin-3-one, 4-Bromo-2-(2,5-dichlorophenyl)-5-hydroxypyridazin-3-one; glaucoma or ocular hypertension | ALLERGAN, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| EP-2010165-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| WO-2007014226-A2 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATION AND STROKE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-0413244-A2 | Process for separation and recycling of by-products from the wastewater of the synthesis of 5-amino-4-chloro-2-phenyl-3(2H)-pyridazinone | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
| EP-0413244-A2 | Process for separation and recycling of by-products from the wastewater of the synthesis of 5-amino-4-chloro-2-phenyl-3(2H)-pyridazinone | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | RAB9A 342/4885ALDH1A1 3297/4885SMN1; SMN2 4837/4885 |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | RAB9A 2534/4885ALDH1A1 1519/4885SMN1; SMN2 89/4885 |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | RAB9A 2534/4885ALDH1A1 1519/4885SMN1; SMN2 89/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | RAB9A 342/4885ALDH1A1 3297/4885SMN1; SMN2 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.